Canada markets close in 41 minutes

Corvus Pharmaceuticals Inc (C17.BE)

Berlin - Berlin Delayed Price. Currency in EUR
Add to watchlist
1.6500+0.1800 (+12.24%)
As of 08:30PM CEST. Market open.
Show:
Balance Sheet
Cash Flow
Annual

Income Statement

All numbers in thousands
Breakdown
ttm
2023-12-31
2022-12-31
2021-12-31
2020-12-31
Total Revenue
0
0
0
0
0
Operating Expenses
Research Development
16,526
16,526
24,468
29,115
31,830
Selling General and Administrative
6,881
6,881
8,097
9,515
11,930
Total Operating Expenses
23,407
23,407
32,565
38,630
43,760
Operating Income or Loss
-23,407
-23,407
-32,565
-38,630
-43,760
Interest Expense
-
-
-
15
-
Total Other Income/Expenses Net
-5,206
-5,206
-9,396
-4,596
37,225
Income Before Tax
-27,029
-27,029
-41,307
-43,241
-5,995
Income from Continuing Operations
-27,029
-27,029
-41,307
-43,241
-5,995
Net Income
-27,029
-27,029
-41,307
-43,241
-5,995
Net Income available to common shareholders
-27,029
-27,029
-41,307
-43,241
-5,995
Basic EPS
-0.64
-0.56
-0.89
-1.03
-0.20
Diluted EPS
-0.64
-0.56
-0.89
-1.03
-0.20
Basic Average Shares
47,401
48,025
46,554
41,854
29,479
Diluted Average Shares
47,401
48,025
46,554
41,854
29,479